论文部分内容阅读
To accelerate our endeavors to overcome cancer,Chinese Journal of Cancer has launched a program of publishing 150 most important questions in cancer research and clinical oncology.In this article,9 more questions are presented as follows.Question 31:How does aging process inhibit the formation of sarcoma? Question 32:Is intratumoral morphological heterogeneity the consequence of tumor genomic instability or the cause of aggressive tumor behavior?Can we identify more aggressive tumors by computationally analyzing the morphological heterogeneity of the tumor tissues? Question 33:How to pre-surgically differentiate irradiation-induced ulceration from cancerous ulceration? Question 34:Why is epidermal growth factor receptor(EGFR) 19 Del-positive tumor more sensitive to targeted therapy than EGFR 21 L858R-positive tumor in patients with non-small cell lung cancer? Question 35:Can an EpsteinBarr virus vaccine be developed to reduce the incidence of EBV-related malignancies? Question 36:What is the unique feature in sarcoma vasculature that causes the intrinsic resistance of sarcoma against anti-angiogenic therapy?Question 37:How many ways can sarcoma cells protect themselves from the attacks of cytotoxic drugs? Question 38:How stable does the tumor heterogeneity remain along with cytotoxic chemotherapy? Question 39:How to generate a prognostic classifier for diffuse low-grade gliomas by integrating genetic and epigenetic signatures with histological features?
To accelerate our endeavors to overcome cancer, Chinese Journal of Cancer has launched a program of publishing 150 most important questions in cancer research and clinical oncology. In this article, 9 more questions are presented as follows. Question 31: How does aging process inhibit the formation of sarcoma? Question 32: Is intratumoral morphological heterogeneity the consequence of tumor genomic instability or the cause of aggressive tumor behavior? Can we identify more aggressive tumors by computationally analyzing the morphological heterogeneity of the tumor tissues? Question 33: How to pre-surgically Question 34: Why is epidermal growth factor receptor (EGFR) 19 Del-positive tumor more sensitive to targeted therapy than EGFR 21 L858R-positive tumor in patients with non-small cell lung cancer? Question 35 : Can an Epstein Barr virus vaccine be developed to reduce the incidence of EBV-related malignancies? Question 36: What is the unique feature in sarcoma vasculature that causes the intrinsic resistance of sarcoma against anti-angiogenic therapy? Question 37: How many ways can sarcoma cells protect themselves from the attacks of cytotoxic drugs? Question 38: How stable does the tumor heterogeneity remain along with with Question 39: How to generate a prognostic classifier for diffuse low-grade gliomas by integrating genetic and epigenetic signatures with histological features?